Filing Details

Accession Number:
0001576280-21-000045
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-26 17:35:33
Reporting Period:
2021-04-23
Accepted Time:
2021-04-26 17:35:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576280 Guardant Health Inc. GH Services-Medical Laboratories (8071) 454139254
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1752968 Helmy Eltoukhy 505 Penobscot Drive
Redwood City CA 94063
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-04-23 7,388 $160.12 1,828,514 No 4 S Direct
Common Stock Disposition 2021-04-26 751 $160.01 1,827,763 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 365,775 Indirect Shares held by Eltoukhy Investments, L.P.
Footnotes
  1. These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.00 to $160.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.00 to $160.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.